4.5 Review

Regulation of inflammation by interleukin-4: a review of alternatives

期刊

JOURNAL OF LEUKOCYTE BIOLOGY
卷 92, 期 4, 页码 753-764

出版社

WILEY
DOI: 10.1189/jlb.0412214

关键词

alternative splicing; interelukin-4 receptor; interleukin-4 signaling; alternative macrophage activation

资金

  1. VA Merit Award [5I01CX000101, 5I01CX000107]
  2. U.S. National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases [1R03AR054946]
  3. U.S. National Institutes of Health, NIAID [RO1AI038985, 2RO1AI049316]
  4. U.S. National Institutes of Health, National Heart, Lung, and Blood Institute [1R21HL106196]

向作者/读者索取更多资源

Studies of IL-4 have revealed a wealth of information on the diverse roles of this cytokine in homeostatic regulation and disease pathogenesis. Recent data suggest that instead of simple linear regulatory pathways, IL-4 drives regulation that is full of alternatives. In addition to the well-known dichotomous regulation of Th cell differentiation by IL-4, this cytokine is engaged in several other alternative pathways. Its own production involves alternative mRNA splicing, yielding at least two functional isoforms: full-length IL-4, encoded by the IL-4 gene exons 1-4, and IL-4 delta 2, encoded by exons 1, 3, and 4. The functional effects of these two isoforms are in some ways similar but in other ways quite distinct. When binding to the surface of target cells, IL-4 may differentially engage two different types of receptors. By acting on macrophages, a cell type critically involved in inflammation, IL-4 induces the so-called alternative macrophage activation. In this review, recent advances in understanding these three IL-4-related branch points-alternative splicing of IL-4, differential receptor engagement by IL-4, and differential regulation of macrophage activation by IL-4-are summarized in light of their contributions to inflammation. J. Leukoc. Biol. 92: 753-764; 2012.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据